154 results on '"Giraudet, Anne-Laure"'
Search Results
2. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)
3. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
4. Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma
5. Performance study of a 360° CZT camera for monitoring 177Lu-PSMA treatment
6. From netrin‐1‐targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors
7. PRadR: PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer, a multicentric phase I/II.
8. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for 177Lu-DOTATATE therapy
9. Unintentional Intra-arterial Injection of 177Lu-PSMA-1 in a Patient With a Peritoneal Carcinosis Secondary to a Metastatic Prostate Cancer
10. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations
11. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network
12. Predictive factors of outcome in poorly differentiated thyroid carcinomas
13. Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma.
14. Phase II study of 131I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP
15. Performance study of a 360° CZT camera for monitoring 177Lu-PSMA treatment
16. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery
17. PET imaging for thyroid cancers: Current status and future directions
18. Real-life data on [ 177 Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.
19. From netrin‐1‐targeted SPECT / CT to internal radiotherapy for management of advanced solid tumors
20. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma
21. Phase II study of 131I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP.
22. Performance study of a 360° CZT camera for monitoring 177Lu-PSMA treatment.
23. Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.
24. Phase III study of18F-PSMA-1007 versus18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study
25. Unintentional Intra-arterial Injection of 177Lu-PSMA-1 in a Patient With a Peritoneal Carcinosis Secondary to a Metastatic Prostate Cancer
26. Intense Diffuse Lung Uptake Due to Interstitial Pneumopathy Related to Polyangiitis Granulomata in 68Ga-PSMA-11 PET/CT
27. Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT
28. Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma.
29. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
30. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
31. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study.
32. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for $$^{177}$$Lu-DOTATATE therapy
33. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer
34. 18F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer
35. Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study
36. Incidental Finding of Hibernoma in Prostate-Specific Membrane Antigen PET/CT
37. Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients?: Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745)
38. Intense Diffuse Lung Uptake Due to Interstitial Pneumopathy Related to Polyangiitis Granulomata in 68 Ga-PSMA-11 PET/CT.
39. PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
40. Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions
41. Single photon emission tomography/computed tomography (SPET/CT) and positron emission tomography/computed tomography (PET/CT) to image cancer
42. Breast Cancer Recurrence Diagnosis Suspected on Tumor Marker Rising: Value of Whole-Body 18FDG-PET/CT Imaging and Impact on Patient Management
43. Unintentional Intra-arterial Injection of 177 Lu-PSMA-1 in a Patient With a Peritoneal Carcinosis Secondary to a Metastatic Prostate Cancer.
44. Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels
45. Intense Diffuse Lung Uptake Due to Interstitial Pneumopathy Related to Polyangiitis Granulomata in 68Ga-PSMA-11 PET/CT
46. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma
47. FDOPA Patterns in Adrenal Glands
48. SYNFRIZZ: A first-in-human (FIH) study of a radiolabeled monoclonal antibody (Mab) targeting frizzled homolog 10 (FZD10) in patients (pts) with advanced synovial sarcomas (SyS).
49. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1
50. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.